Amit Oza, MD, MBBS, FRCPC, Discusses Optimizing Treatment With PARP Inhibitors in Advanced Ovarian Cancer
PARP inhibitors like rucaparib should be considered to treat all kinds of patients, including those who have deleterious mutations and HRD, according to Amit Oza, MD, MBBS, FRCPC.
Amit Oza, MD, MBBS, FRCPC, Highlights the Benefit of Early Maintenance PARP Inhibitor Use in Ovarian Carcinoma
PARP inhibitors such as rucaparib appear to garner the most benefit in the early maintenance setting in patients with ovarian cancer who have less advanced disease and less heterogeneity, according to Amit Oza, MD, MBBS, FRCPC.